Myelomax is a preclinical CRO specializing in Multiple Myeloma target candidate testing and evaluation services for pharmaceutical and biotech companies, and research organizations who are working to advance therapies for Multiple Myeloma.
Unlike other generalist or non-specialist preclinical contract research organsinions, Myelomax is the only preclinical CRO wholly dedicated to Multiple Myeloma. This means we are well placed to provide unique expertise to pharmaceutical and biotech companies, and research institutions who wish to evaluate in vitro and in vivo the clinical potential of target candidates for Multiple Myeloma.
Spin-off created in 2011
Conducted over 1600 assay tests to date
Evaluated over 34 molecules
Why this focus on Multiple Myeloma?
Each year worldwide more than 115,000 people are newly diagnosed with Multiple Myeloma, a type of blood cancer that develops from plasma cells in bone marrow. Recent advances in treatment mean that survival rates have significantly improved to between 5 and 9 years. However with time patients relapse as treatments fail to work over the long term meaning that for most patients the disease remains incurable. Over 220 people still die each day from Multiple Myeloma – the equivalent of 1 to 2% of all cancer related deaths in Western countries.